More than 9 months into the combat against COVID-19, the world has seen battles being stepped up on all fronts in the search for an effective therapy. While new drugs are being developed, old drugs are repurposed as potential treatment for COVID-19, and a plethora others are upcoming in the pipeline.
Initiation of sacubitril-valsartan combo during hospitalization in Asian patients with heart failure with reduced ejection fraction (HFrEF) appears to lead to a higher incidence of adverse drug reactions (ADRs) and treatment discontinuation when compared with starting the patients on the drug as an outpatient, according to real-world data.
An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]
Durvalumab with or without tremelimumab in the first-line setting does not improve overall survival (OS) over standard-of-care (SoC) chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma, according to the phase III DANUBE trial.
Having vaccination against influenza during pregnancy was not associated with an increased risk of autism spectrum disorder (ASD) in the offspring, a large cohort study reveals — providing more support for vaccination during pregnancy.
The novel, next-generation, highly potent and selective RET inhibitor selpercatinib may modify the landscape of another genomic subgroup — RET-altered cancers, according to two early-phase trials investigating the potential of selpercatinib in medullary thyroid cancer (MTC) and non-small-cell lung cancer (NSCLC).
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Use of alpha blockers in patients with chronic kidney disease (CKD) appears to be both beneficial and detrimental, with a recent study linking it to lower risk of cardiac events and mortality but higher risk of kidney disease progression compared with alternative blood pressure-lowering medications.
Intensive insulin titration with fast-acting insulin aspart (faster aspart) provided effective overall glycaemic control, superior post-prandial glucose (PPG) control, and a lower rate of severe or blood glucose (BG)-confirmed hypoglycaemia vs insulin aspart (IAsp), in combination with insulin degludec with or without metformin, in adults with advanced type 2 diabetes (T2D) not optimally controlled with a basal-bolus regimen, according to the ONSET 9 trial.
Interim results of REGENERATE* trial highlight the ability of experimental noninvasive tests to evaluate treatment response in adults with NASH** and advanced liver fibrosis who are receiving obeticholic acid (OCA).
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.